A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms. TAVALISSE® (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Japan, the Republic of Korea (Korea), Canada and Israel (as TAVALISSE) for the treatment of chronic ITP in adult patients.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 294M | 294M | 179M | 117M | 120M | 149M |
| Net Income | 367M | 367M | 17M | -25M | -59M | -18M |
| EPS | $19.48 | $19.48 | $0.99 | $-1.44 | $-3.40 | $-1.10 |
| Free Cash Flow | 76M | 76M | 31M | -5.7M | -74M | 5.3M |
| ROIC | 93.7% | 91.4% | 14.0% | -13.8% | -32.7% | -35.6% |
| Gross Margin | 93.3% | 93.3% | 89.6% | 93.9% | 98.5% | 99.3% |
| Debt/Equity | 0.13 | 0.13 | 18.15 | -2.08 | -2.90 | 0.66 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 125M | 125M | 24M | -20M | -56M | -12M |
| Operating Margin | 42.6% | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% |
| ROE | 93.8% | 185.9% | 531.8% | - | - | -59.0% |
| Shares Outstanding | 19M | 19M | 18M | 17M | 17M | 16M |
RIGEL PHARMACEUTICALS INC passes 6 of 9 quality checks, suggesting mixed fundamentals.
RIGEL PHARMACEUTICALS INC trades at 1.6x trailing earnings, compared to its 15-year median P/E of 9.5x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 7.8x vs a median of 11.0x. The company's 5-year average ROIC is 4.7% with a gross margin of 94.9%. At current prices, the estimated annualized return to fair value is +247.2%.
RIGEL PHARMACEUTICALS INC (RIGL) has a current P/E ratio of 1.6, compared to its historical median P/E of 9.5. The stock is currently considered Cheap based on its historical valuation range.
RIGEL PHARMACEUTICALS INC (RIGL) has a 5-year average return on invested capital (ROIC) of 4.7%. This is below average and may indicate limited pricing power.
RIGEL PHARMACEUTICALS INC (RIGL) has a market capitalization of $591M. It is classified as a small-cap stock.
RIGEL PHARMACEUTICALS INC (RIGL) does not currently pay a regular dividend.
Based on historical P/E analysis, RIGEL PHARMACEUTICALS INC (RIGL) appears cheap. The current P/E of 1.6 is 83% below its historical median of 9.5. The estimated fair value CAGR (P/E method) is 400.2%.
RIGEL PHARMACEUTICALS INC (RIGL) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
RIGEL PHARMACEUTICALS INC (RIGL) reported annual revenue of $294 million in its most recent fiscal year, based on SEC EDGAR filings.
RIGEL PHARMACEUTICALS INC (RIGL) has a net profit margin of 124.7%. This is a strong margin indicating high profitability.
RIGEL PHARMACEUTICALS INC (RIGL) generated $76 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
RIGEL PHARMACEUTICALS INC (RIGL) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
RIGEL PHARMACEUTICALS INC (RIGL) reported earnings per share (EPS) of $19.48 in its most recent fiscal year.
RIGEL PHARMACEUTICALS INC (RIGL) has a return on equity (ROE) of 185.9%. This indicates the company generates strong returns for shareholders.
RIGEL PHARMACEUTICALS INC (RIGL) has a 5-year average gross margin of 94.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for RIGEL PHARMACEUTICALS INC (RIGL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RIGEL PHARMACEUTICALS INC (RIGL) has a book value per share of $20.78, based on its most recent annual SEC filing.